The DOI matches its Crossref record.
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Open accessAbstract
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for suboptimal response. The estimated cumulative incidences of complete cytogenetic response (CCR) by 12 and 24 months were 88% and 90%, and major molecular responses (MMRs) were 47% and 73%. In patients who maintained a daily average of 600 mg of imatinib for the first 6 months (n = 60), MMR rates by 12 and 24 months were 55% and 77% compared with 32% and 53% in patients averaging less than 600 mg (P = .037 and .016, respectively). Dose escalation was indicated for 17 patients before 12 months for failure to achieve, or maintain, major cytogenetic response at 6 months or CCR at 9 months but was only possible in 8 patients (47%). Dose escalation was indicated for 73 patients after 12 months because their BCR-ABL level remained more than 0.01% (international scale) and was possible in 45 of 73 (62%). Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationHasford, J., Baccarani, M., Hoffmann, V., Guilhot, J., Saussele, S., Rosti, G., Guilhot, F., Porkka, K., Ossenkoppele, G., Lindoerfer, D., et al. (2011) · Blood · doi:10.1182/blood-2010-12-319038 · Cited by 500
Eichhorst, B., Hallek, M., & Dreyling, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 341
Metadata
- Authors
- Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M. F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A. K., Fay, K., Durrant, S., Januszewicz, H., Joske, D., Underhill, C., Dunkley, S., Lynch, K., & Grigg, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-11-15
- Volume
- 112
- Issue
- 10
- Pages
- 3965-3973
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1986635169
- Cited by
- 180
- References
- 0
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. https://app.cochat.ai/papers/10.1182/blood-2008-06-161737
- The paper
- Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M. F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A. K., Fay, K., Durrant, S., . . . Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. https://doi.org/10.1182/blood-2008-06-161737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.